หน้าแรก
ค้นหา
Dr. Hope Rugo on Trastuzumab Biosimilar in HER2-Positive Breast Cancer
No description available
แสดงข้อมูลเพิ่มเติม 1
Dr. Hope Rugo on Trastuzumab Biosimilar in HER2-Positive Breast Cancer
Dr. Hope Rugo on Safety of Trastuzumab Biosimilar for HER2+ Breast Cancer
Optimizing Therapy in HER2+ Disease with Dr. Hope S. Rugo
Hope S. Rugo, et al.
Dr. Rugo Discusses the Regulatory Process Behind Biosimilars
Novel Strategies for HER2+ Metastatic Breast Cancer; Biosimilars
At ASCO 2019, Dr. Hope Rugo presents on results of the SOPHIA breast cancer study
INspired | Beyond the White Coat with Dr. Hope Rugo
Dr. Rugo on the Phase III SOPHIA Trial in HER2+ Breast Cancer
SABCS 2017 roundtable with Dr. Hope S. Rugo and Dr. William J. Gradishar
Dr. Rugo Discusses a Comparative Review of Trastuzumab Biosimilars
Dr. Hope Rugo on Comparative Effectiveness in the NSABP B-38 Trial
Dr. Rugo on Ongoing Trials in HER2+ Breast Cancer
Rugo: De-escalating Systemic Therapy for Breast Cancer
Dr. Rugo on Pathway Blockade in Breast Cancer
SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive MBC after prior ant...
Findings of a Biosimilar Trastuzumab Study in Patients With HER2-Positive Breast Cancer
Dr. Rugo on 20-Year Span of Breast Cancer Advancements
Hope Rugo, MD: Advances and Challenges In the Treatment of Metastatic Breast Cancer
Hope S. Rugo on the Approval of the Cooling Cap
